Study: Oregon Would Double Marijuana Supply If All Producer Licenses Allotted

A new study of the economics of Oregon’s recreational cannabis industry shows the state would nearly double its cannabis supply if regulators approved all pending producer applications, which could potentially strain an already glutted market.

Oregon’s market has struggled with oversupply issues, driving prices down for adult-use cannabis growers and attracting pressure from federal regulators concerned about diversion of cannabis out of state.

The study, released Wednesday, suggests the oversupply situation is unlikely to change anytime soon.

The report comes as state regulators and policymakers have raised the idea of imposing caps on the number of business licenses and curbing – or even reducing – canopy size limits for growers.

Here are some key findings from the biennial Recreational Marijuana Supply and Demand Legislative Report, conducted by the Oregon Liquor Control Commission, which regulates the state’s marijuana program:

Between July 2017 and June 2018, recreational cannabis demand represented 50% of supply; the other 50% remained accounted for in recreational licensees’ inventory and contained within the recreational system.
Licensed recreational producers harvested more than 2,000 metric tons of wet, untrimmed marijuana in 2018; if all currently pending producer applications were approved, estimated production would increase to nearly 4,000 metric tons of wet weight.
As of Jan. 1, 2019, the recreational market has 6½ years worth of theoretical supply in licensees’ inventory accounted for and contained within Oregon’s cannabis tracking system.
An estimated 55% of total statewide marijuana consumption among Oregonians 21 or older is procured from recreational cannabis retailers versus the black market. Based on existing levels of production, all consumption of marijuana among Oregon adults could be supplied by the legal market.
Increased supply has resulted in consumer prices falling from more than $10 per gram of marijuana in October 2016 to less than $5 per gram in December 2018. Despite those falling prices, the overall sales have continued to increase year-over-year, rising nearly 16% between December 2017 and December 2018.

The report also notes that “even under assumptions of growth in demand caused by more Oregonians consuming more marijuana, supply will almost certainly continue to exceed demand at current levels of production.”

Original Article Source: https://mjbizdaily.com/study-oregon-would-double-marijuana-supply-if-all-producer-licenses-allotted/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog